Cancer cells are metabolically different from normal cells, including the Warburg effect and uses glutamine to fill the tricarboxylic acid (TCA) cycle. It was demonstrated inhibiting glutamine metabolism prevents tumor growth. The mammalian target of rapamycin (mTOR) is one of the signaling pathways that involve glutamine metabolism in cancer. On the other hand, the carbon quantum dots (CQ-dots) nanoparticles can be used in cancer detection and treatment. These nanoparticles are associated with the mTOR signaling pathway too. The findings indicate that irregular glutamine metabolism is related to the growth of colorectal cancer (CRC). Thus, the activating glutamine metabolism via the mTOR pathway in CQ-dots treatments has toxic effect on CRC therapy. So, more investigations are needed for the therapeutic application of these nanocarriers as drug delivery systems.